Focal Segmental Glomerulosclerosis Market Forecast Reveals Where Future Industry Value Will Be Created
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Focal Segmental Glomerulosclerosis Market Growth Potential: How Will Market Size Change Through 2030?
The market for focal segmental glomerulosclerosis has experienced robust expansion over recent years, increasing from $1.57 billion in 2025 to $1.69 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.6%. This historical growth has been driven by factors such as the prevalence of proteinuria, the burden of chronic kidney disease, the utilization of corticosteroids, the growth of nephrology clinics, and the development of dialysis infrastructure.
The market for focal segmental glomerulosclerosis is projected to experience robust expansion in the coming years, reaching a value of $2.24 billion by 2030 with a compound annual growth rate (CAGR) of 7.2%. This anticipated growth during the forecast period is driven by advancements in precision nephrology, the identification of early disease biomarkers, progress in biologic drug development, the expansion of transplant programs, and increased funding for rare kidney disease research. Key trends shaping this period include a heightened emphasis on targeted immunosuppressive therapy, a growing preference for combination drug regimens, broader implementation of early diagnostic screening, greater utilization of renin-angiotensin system inhibitors, and improved preparedness for kidney transplants.
Download A Free Sample Report For Comprehensive Market Insights:
Focal Segmental Glomerulosclerosis Market Expansion Supported By Key Demand Factors
The increasing occurrence of kidney disease is anticipated to accelerate the expansion of the focal segmental glomerulosclerosis market in the coming years. Kidney diseases are defined as disorders that compromise the kidneys’ functionality and structure, hindering their capacity to eliminate waste, regulate fluid balance, and maintain vital physiological processes. This surge in kidney disease cases is largely attributed to diabetes since prolonged high blood sugar levels harm the renal filtering units, causing diabetic nephropathy. Focal segmental glomerulosclerosis describes the advancing formation of scar tissue within the kidney filters, functioning as a crucial marker and focus for comprehending, diagnosing, and treating chronic kidney conditions. For example, in August 2025, according to the American Kidney Fund, a nonprofit organization based in the United States, 35.5 million Americans are currently affected by chronic kidney disease (CKD), approximately 815,000 Americans have kidney failure, and nearly 555,000 Americans are undergoing dialysis. Consequently, the growing prevalence of kidney diseases is fueling the focal segmental glomerulosclerosis market.
Focal Segmental Glomerulosclerosis Market Segment Performance And Strategic Opportunities
The focal segmental glomerulosclerosis market covered in this report is segmented –
1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis
2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments
3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids
4) By Route Of Administration: Oral, Parenteral
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant
2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes
Focal Segmental Glomerulosclerosis Market Growth Trends Influencing Competitive Dynamics
Leading players in the focal segmental glomerulosclerosis market are concentrating on creating novel therapies, including non-immunosuppressive oral medications, aimed at enhancing patient outcomes and minimizing side effects associated with treatment. Non-immunosuppressive oral medication refers to a drug taken orally that addresses disease without compromising the immune system, assisting in managing focal segmental glomerulosclerosis by directly targeting kidney damage while avoiding immune-related adverse effects. As an example, in May 2025, Travere Therapeutics Inc., a biopharmaceutical company based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), which received traditional approval for treating focal segmental glomerulosclerosis (FSGS). FILSPARI represents a first-of-its-kind therapy that operates by concurrently inhibiting both the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual-action mechanism substantially lowers proteinuria in conditions like FSGS and IgA nephropathy. When measured against current treatments, FILSPARI delivers superior kidney protection while preserving a favorable safety profile with fewer immune-related complications.
Focal Segmental Glomerulosclerosis Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.
Access The Complete Focal Segmental Glomerulosclerosis Market Report:
Focal Segmental Glomerulosclerosis Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the focal segmental glomerulosclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the focal segmental glomerulosclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
